The study, published Jan. 10 in JAMA, found 1 in 4 “loophole” approvals has been based on medical devices that later were recalled. These include Class I recalls where the FDA concluded using the device could cause harm or death.
Moreover, the newly authorized medical devices were then used to support approval for the next generation of similar devices — which also were later recalled.
Researchers reviewed the regulatory history of all medical devices subjected to Class I recalls between 2018 and 2021 and found “safety issues were pervasive.”
Harlan Krumholz, MD, director of the Yale Center for Outcomes Research and Evaluation at Yale School of Medicine, said loophole is a legal issue, “not an FDA issue.”
Closing the loophole would require action by Congress.
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.